CN104017787B - 一类新颖的以蛋白质为基础的治疗用分子 - Google Patents

一类新颖的以蛋白质为基础的治疗用分子 Download PDF

Info

Publication number
CN104017787B
CN104017787B CN201310239638.6A CN201310239638A CN104017787B CN 104017787 B CN104017787 B CN 104017787B CN 201310239638 A CN201310239638 A CN 201310239638A CN 104017787 B CN104017787 B CN 104017787B
Authority
CN
China
Prior art keywords
sialidase
protein
domain
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN201310239638.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104017787A (zh
Inventor
房芳
迈克尔·马拉科夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ansun Biopharma Inc
Original Assignee
Ansun Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ansun Biopharma Inc filed Critical Ansun Biopharma Inc
Publication of CN104017787A publication Critical patent/CN104017787A/zh
Application granted granted Critical
Publication of CN104017787B publication Critical patent/CN104017787B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN201310239638.6A 2004-09-10 2005-07-21 一类新颖的以蛋白质为基础的治疗用分子 Expired - Lifetime CN104017787B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/939,262 2004-09-10
US10/939,262 US7807174B2 (en) 2002-11-22 2004-09-10 Class of therapeutic protein based molecules
CN2005800372268A CN101426906B (zh) 2004-09-10 2005-07-21 一类新颖的以蛋白质为基础的治疗用分子

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2005800372268A Division CN101426906B (zh) 2004-09-10 2005-07-21 一类新颖的以蛋白质为基础的治疗用分子

Publications (2)

Publication Number Publication Date
CN104017787A CN104017787A (zh) 2014-09-03
CN104017787B true CN104017787B (zh) 2017-03-29

Family

ID=36060467

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310239638.6A Expired - Lifetime CN104017787B (zh) 2004-09-10 2005-07-21 一类新颖的以蛋白质为基础的治疗用分子
CN2005800372268A Expired - Lifetime CN101426906B (zh) 2004-09-10 2005-07-21 一类新颖的以蛋白质为基础的治疗用分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2005800372268A Expired - Lifetime CN101426906B (zh) 2004-09-10 2005-07-21 一类新颖的以蛋白质为基础的治疗用分子

Country Status (16)

Country Link
US (2) US7807174B2 (https=)
EP (4) EP3530734A1 (https=)
JP (2) JP4764881B2 (https=)
KR (1) KR20070064619A (https=)
CN (2) CN104017787B (https=)
AU (1) AU2005285461B2 (https=)
BR (1) BRPI0515646B8 (https=)
CA (2) CA2823429C (https=)
DK (3) DK1786902T3 (https=)
ES (3) ES2554787T3 (https=)
IL (3) IL181779A (https=)
PT (3) PT3018204T (https=)
RU (1) RU2468080C2 (https=)
TR (1) TR201905393T4 (https=)
WO (1) WO2006031291A2 (https=)
ZA (1) ZA200702915B (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210528A1 (en) * 1999-03-05 2010-08-19 Leland Shapiro Compositions, methods and uses for inhibition and/or treatment of influenza infection
US8512710B2 (en) * 2002-11-22 2013-08-20 Ansun Biopharma, Inc. Class of therapeutic protein based molecules
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
WO2004047735A2 (en) * 2002-11-22 2004-06-10 Mang Yu Broad spectrum anti-viral therapeutics and prophylaxis
WO2006051864A1 (ja) * 2004-11-10 2006-05-18 Hitachi Chemical Co., Ltd. 接着補助剤付金属箔及びそれを用いたプリント配線板
KR20080083266A (ko) * 2005-10-25 2008-09-17 엠엔디 다이어그노스틱 리미티드 인플루엔자 바이러스의 검출용 조성물 및 이를 이용한 키트및 방법
AU2015215955B2 (en) * 2006-01-24 2016-12-01 Ansun Biopharma, Inc. Technology for preparation of macromolecular microspheres
AU2013237761B8 (en) * 2006-01-24 2015-06-04 Ansun Biopharma, Inc. Technology for preparation of macromolecular microspheres
KR101501780B1 (ko) * 2006-01-24 2015-03-16 넥스바이오, 인코퍼레이티드 고분자 미소 구체들의 조제를 위한 기술
US8273381B1 (en) * 2006-04-14 2012-09-25 Auburn University Compositions for and methods of controlling olfactory responses to odorants
US20100143972A1 (en) * 2006-12-14 2010-06-10 Horswill Alexander R Method of Making Cyclic Polypeptides with Inteins
BRPI0807768A2 (pt) * 2007-02-20 2014-06-24 Dsm Ip Assests Bv Nova sialidase.
EP2178852B9 (en) 2007-08-03 2016-06-22 Romark Laboratories, L.C. Alkylsulfonyl-substituted thiazolide compounds
PE20121118A1 (es) * 2009-05-12 2012-09-05 Romark Lab Lc Compuestos de haloalquil heteroaril benzamida
AP2012006064A0 (en) * 2009-06-26 2012-02-29 Romark Lab Lc Compounds and methods for treating influenza.
US20110171718A1 (en) * 2009-07-31 2011-07-14 Danisco Us Inc. Proteases With Modified Pre-Pro Regions
JP2013510169A (ja) * 2009-11-06 2013-03-21 ネクスバイオ，インク． 呼吸器管の治療及び予防のための方法、化合物、及び組成物
US20130280332A1 (en) * 2012-02-17 2013-10-24 Nexbio, Inc. Methods, Compounds and Compositions for Treatment of Influenza and Parainfluenza Patients
EP2866792A4 (en) 2012-06-28 2016-08-17 Ansun Biopharma Inc MICROPARTICLE FORMULATIONS FOR DELIVERY TO LOWER AND CENTRAL RESPIRATORY PATHS AND METHOD OF PREPARING THEM
WO2014005107A2 (en) * 2012-06-28 2014-01-03 Ansun Biopharma, Inc. Microparticle formulations for delivery to the upper and central respiratory tract and methods of manufacture
CA3185756A1 (en) 2012-12-24 2014-07-03 Coagulant Therapeutics Corporation Short-acting factor vii polypeptides
EP2970857A4 (en) 2013-03-15 2016-11-02 Ansun Biopharma Inc NEW PROTEIN CLEANING PROCESS
PT3524617T (pt) 2013-03-15 2023-07-12 Gladiator Biosciences Inc Domínios gla como agentes terapêuticos
WO2014197485A1 (en) * 2013-06-03 2014-12-11 Ansun Biopharma, Inc. Anti-viral therapeutic for infection of the eye
US10300116B2 (en) 2013-06-10 2019-05-28 Ansun Biopharma, Inc. Treatment for BK polyomavirus infection
WO2014201027A2 (en) * 2013-06-10 2014-12-18 Ansun Biopharma, Inc. Treatment of merkel cell polyomavirus infection
WO2015184356A1 (en) 2014-05-30 2015-12-03 Ansun Biopharma, Inc. Treatment of middle east respiratory syndrome coronavirus
WO2016044656A1 (en) 2014-09-17 2016-03-24 Ansun Biopharma, Inc. Treatment of infection by human enterovirus d68
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
WO2016115616A1 (en) * 2015-01-21 2016-07-28 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Inhibition of cellular proteases as treatment for influenza
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
SG10202100652VA (en) 2015-07-21 2021-03-30 Univ Jefferson Gene therapies for neurodegenerative disorders targeting ganglioside biosynthetic pathways
ES2938890T3 (es) 2016-05-20 2023-04-17 Octapharma Ag Proteínas de fusión de VWF glucosiladas con farmacocinética mejorada
MX2018016393A (es) 2016-07-01 2019-08-12 Univ Leland Stanford Junior Conjugados para la edición de la superficie de la celula diana.
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
DK3630968T3 (da) * 2017-05-26 2024-07-29 Genovis Ab Enzymer til glycananalyse
SG11202001535RA (en) * 2017-09-05 2020-03-30 Gladiator Biosciences Inc Method of targeting exosomes
KR102914621B1 (ko) 2018-01-03 2026-01-21 팔레온 파마슈티칼스 인크. 재조합 인간 시알리다제, 시알리다제 융합 단백질, 및 이를 사용하는 방법
GB201800274D0 (en) * 2018-01-08 2018-02-21 Enzymatica Ab Novel treatments
GB201803197D0 (en) 2018-02-27 2018-04-11 Pneumagen Ltd Viral treatment
WO2020018996A2 (en) * 2018-07-20 2020-01-23 Ansun Biopharma, Inc. Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment
CN109991649B (zh) * 2019-03-26 2021-04-06 华中科技大学 一种制备无机闪烁体膜的方法
JP7343890B2 (ja) * 2019-04-26 2023-09-13 国立大学法人東海国立大学機構 シアリダーゼ活性を有する酵素剤及びその利用
CN110038122A (zh) * 2019-05-23 2019-07-23 武汉真福医药股份有限公司 枯草杆菌纤溶酶在治疗支气管炎药物中的应用
CA3145200A1 (en) 2019-07-03 2021-01-07 Aillis Inc. Pharmaceutical composition for treating influenza virus infections
CN111450236B (zh) * 2020-02-25 2023-04-07 西北大学 一种用于阻断冠状病毒感染的制剂
WO2021217053A1 (en) * 2020-04-24 2021-10-28 Rezolute, Inc. Plasma kallikrein inhibitors for the treatment of ards and related conditions
US20230218794A1 (en) * 2020-06-10 2023-07-13 The Penn State Research Foundation Process and system to lessen human coronavirus transmission and spread
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
CN117836432A (zh) * 2021-06-09 2024-04-05 微生物机器公司 用于检测患病细胞的工程化微生物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1191572A (zh) * 1995-07-05 1998-08-26 安多齐莫有限公司 具有噬菌体内切唾液酸酶活力的重组蛋白
CN1405562A (zh) * 2002-10-24 2003-03-26 肖洪武 一种唾液酸酶测定试剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3439089A (en) 1968-03-27 1969-04-15 Merck & Co Inc Medicated hard candy
US5643758A (en) 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
EP0286239B1 (en) * 1987-03-10 1996-03-13 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
RU2054180C1 (ru) 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций
US5376633A (en) 1992-09-30 1994-12-27 Lezdey; John Method for deactivating viruses in blood component containers
US5985859A (en) * 1994-04-14 1999-11-16 The University Of Alabama Methods of inhibiting bacterial sialidase
BR9506262A (pt) * 1994-06-14 1997-08-12 Gist Brocades Bv Xilanase sequência de dna isolada e purificada vetor células hospedeira microbiana microorganismo isolado processos para a preparação de uma xilanase para a degradação de xilano para deslignificar pasta de madeira e produto obtido após o tratamento da pasta de madeira
BR9607098B8 (pt) * 1995-02-27 2014-11-18 Gilead Sciences Inc Composto e composição farmacêutica.
AU5546898A (en) 1997-01-14 1998-08-07 Hopital Sainte-Justine Human lysosomal sialidase and therapeutic uses thereof
US6251392B1 (en) 1997-10-20 2001-06-26 Epicyte Pharmaceuticals, Inc. Epithelial cell targeting agent
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
US20020025320A1 (en) 1999-08-20 2002-02-28 Prosper Boyaka Sialidases as mucosal adjuvants
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
WO2004047735A2 (en) 2002-11-22 2004-06-10 Mang Yu Broad spectrum anti-viral therapeutics and prophylaxis
DE10258400A1 (de) * 2002-12-13 2004-06-24 N.V. Nutricia Trans-Sialidasen aus Trypanosoma congolense
KR101501780B1 (ko) 2006-01-24 2015-03-16 넥스바이오, 인코퍼레이티드 고분자 미소 구체들의 조제를 위한 기술

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1191572A (zh) * 1995-07-05 1998-08-26 安多齐莫有限公司 具有噬菌体内切唾液酸酶活力的重组蛋白
CN1405562A (zh) * 2002-10-24 2003-03-26 肖洪武 一种唾液酸酶测定试剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Complete nucleotide sequence of the actinomyces viscosus T14V sialidase gene:Presence of a conserved repeating sequence among strains of Actinomyces;Yeung M K 等;《Infection and immunity》;19931231;第61卷(第1期);109-116 *

Also Published As

Publication number Publication date
US20050112751A1 (en) 2005-05-26
US20090142327A1 (en) 2009-06-04
CN101426906B (zh) 2013-06-26
IL181779A0 (en) 2007-07-04
JP5307082B2 (ja) 2013-10-02
BRPI0515646B1 (pt) 2020-10-13
IL241227B (en) 2020-05-31
BRPI0515646B8 (pt) 2021-05-25
RU2007112502A (ru) 2008-10-20
CA2823429C (en) 2019-06-04
JP4764881B2 (ja) 2011-09-07
PT3018204T (pt) 2017-07-13
TR201905393T4 (tr) 2019-05-21
AU2005285461B2 (en) 2011-03-03
PT1786902E (pt) 2015-12-22
WO2006031291A3 (en) 2009-04-16
EP3018204A1 (en) 2016-05-11
DK3241898T3 (en) 2019-04-29
CA2578050C (en) 2015-04-21
JP2010279366A (ja) 2010-12-16
EP3241898A1 (en) 2017-11-08
PT3241898T (pt) 2019-05-20
HK1201562A1 (en) 2015-09-04
IL207957A (en) 2016-10-31
EP1786902B1 (en) 2015-09-09
IL181779A (en) 2015-10-29
CA2578050A1 (en) 2006-03-23
IL241227A0 (en) 2015-11-30
BRPI0515646A8 (pt) 2017-04-04
EP1786902A2 (en) 2007-05-23
DK1786902T3 (en) 2015-10-19
CA2823429A1 (en) 2006-03-23
RU2468080C2 (ru) 2012-11-27
HK1224329A1 (en) 2017-08-18
EP3530734A1 (en) 2019-08-28
EP3018204B1 (en) 2017-04-12
AU2005285461A1 (en) 2006-03-23
DK3018204T3 (en) 2017-07-31
ES2721172T3 (es) 2019-07-29
EP3241898B1 (en) 2019-01-23
ES2626845T3 (es) 2017-07-26
ZA200702915B (en) 2008-11-26
EP1786902A4 (en) 2009-12-09
IL207957A0 (en) 2010-12-30
US7807174B2 (en) 2010-10-05
CN104017787A (zh) 2014-09-03
US7645448B2 (en) 2010-01-12
ES2554787T3 (es) 2015-12-23
BRPI0515646A (pt) 2008-07-15
KR20070064619A (ko) 2007-06-21
CN101426906A (zh) 2009-05-06
JP2008512117A (ja) 2008-04-24
WO2006031291A2 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
CN104017787B (zh) 一类新颖的以蛋白质为基础的治疗用分子
US10525109B2 (en) Class of therapeutic protein based molecules
HK1201562B (en) A novel class of therapeutic protein based molecules
HK1128935A (en) A novel class of therapeutic protein based molecules
HK1128935B (en) A novel class of therapeutic protein based molecules
HK1246351B (en) A novel class of therapeutic protein based molecules
HK1246351A1 (en) A novel class of therapeutic protein based molecules
HK1224329B (en) A novel class of therapeutic protein based molecules

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1201562

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1201562

Country of ref document: HK

CX01 Expiry of patent term

Granted publication date: 20170329

CX01 Expiry of patent term